DUBLIN, Aug. 29, 2023 /PRNewswire/ — The “Global 3D Printed Drugs Market (2023-2028) by Technology, Application, End User, and Geography, Competitive Analysis, Impact of Covid-19 and Ansoff Analysis” report has been added to ResearchAndMarkets.com’s offering.
Global 3D Printed Drugs Market to reach USD USD 74.04 Million In 2023, it is expected that the number of people will reach USD 157.46 Million By 2028 the CAGR will be 16.29%.
3D printed pharmaceuticals are created by 3D printing. This new technique allows precise control of the medication composition. Customized dosages and complex combinations are possible with this technology. The required drug is manufactured by printing layers of active ingredients (APIs), binder and binders. 3D printed pharmaceuticals have the potential of transforming pharmaceutical manufacturing as well as personalized medicine.
The market for 3D printed drugs is driven by the demand for instant soluble drugs. The 3D-printed drug can be transformed into an instant-dissolving structure, which makes it easier to administer, especially for those patients who are having difficulty swallowing the medication or need immediate relief. This technology enables the development of drugs that are fast-soluble, meeting the needs of both patients and healthcare professionals.
The increasing use of 3D-printing technology in the healthcare and medical industries is another important driver for the market of 3D-printed medicines. 3D printing allows for precise dosage form customization. This improves patient care and enables personalized treatment. The versatility of the technology, and its ability build complex drug structure make it a powerful weapon for drug discovery.
The market for 3D-printed medicines is also being driven by the increased use of customized drugs and production of combination medications. 3D printing allows the creation of customized medications, with dosages and compositions tailored to specific patient needs. This technique can also be used to create combination medicines in which multiple drugs are combined and printed into one dosage form. This allows for easier administration of the medication as well as better treatment outcomes. 3D printed medications are in demand because of the push towards personalized and combined therapy.
The market for 3D-printed drugs is a promising one, thanks to the constant technological advancements in 3D printing. Material improvements, printing resolutions, and process optimization make it possible to create more complex and accurate structures for drugs, improving their safety and efficacy.
As healthcare investments increase in emerging markets, the market for 3D printed pharmaceuticals has the potential to grow. These countries invest in 3D printing and other cutting-edge technologies for healthcare infrastructure. These regions could benefit from the use of 3D printed drugs to increase affordability, accessibility and personalized healthcare.
One limitation of 3D printed pharmaceuticals is the possibility of antagonistic pharmacological effect. The interaction between multiple active pharmaceutical components (APIs), in complex drug combination generated by 3D-printing, can result in unexpected effects or reduced effectiveness. This presents issues in drug formulation and safety assurance.
Government regulations that are strict for 3D-printed drugs pose a significant challenge to the 3D-printed pharmaceuticals industry. Due to the uniqueness of 3D printing and its personalized medicine components regulatory organizations are required to create clear standards and criteria regarding quality control, safety and efficacy. This can be difficult. These rules can complicate and prolong the development and commercialization of 3D-printed medicines.
Market Dynamics
Drivers:
- Increased Demand for Instantly Soluble Drugs
- Increasing Use of 3D Printing Techniques in the Medical & Healthcare Industries
- Growing Adoption of Personalized Drugs & Production of Combination Medicine
Restraints:
- Drugs can have antagonistic effects
Opportunities:
- The 3D printing industry is constantly evolving.
- Investments in health care in emerging countries are on the rise
Challenges:
- Three-dimensional printed products are subject to strict government regulations
Companies Mentioned:
- 3D Systems, Corp.
- Abbott Laboratories
- Anatomics, Pty. Ltd.
- Aprecia Pharmaceuticals, LLC
- AstraZeneca
- Bioduro-Sundia
- Biomedical Modelling, Inc.
- Esko
- FabRx Ltd.
- GE Healthcare
- GlaxoSmithKline
- Materialise NV
- Merck Group
- Novartis
- Renishaw PLC
- Siemens Ag
- Stratasys, Ltd.
- Teva Pharmaceuticals Ltd.
- Triastek, Inc.
- Zortrax
Key Attributes
|
Report Attribute |
Details |
|
No. No. |
189 |
|
Forecast Period |
2023 – 2028 |
|
Estimated market value (USD) by 2023 |
$74.04 Milliard |
|
Forecasted Market value (USD), by 2028 |
$157.46 Million |
|
Compound Annual Rate |
16.2 % |
|
Areas covered |
Global |
For more information about this report visit https://www.researchandmarkets.com/r/wlho3x
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world’s leading source for international market research reports and market data. We give you the most recent data on the international and regional market, key industries and top companies.
Media Contact:
Research and Markets
Laura WoodSenior Manager
[email protected]
For E.S.T. Office Hours, Call +1-917-300-0470
Call +1 800 526 8630 for U.S./CAN Toll-Free
To find out the GMT office hours, call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Logo: https://mma.prnewswire.com/media/539438/Research_and_Markets_Logo.jpg
SOURCE Research and Markets
